Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEOGENOMICS INCNEO · Entity 2096 | EVP, GC & Business Development | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEOGENOMICS INC
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 90,875 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 2,692 · Balance 90,875 F1: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the September 1, 2026 vesting of restricted stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.12 · Expires 2026-09-30 | Direct | 1,046 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 1,046 F2: On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.34 · Expires 2027-05-01 | Direct | 1,024 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,024 F3: On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.99 · Expires 2028-05-01 | Direct | 516 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 516 F4: On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.10 · Expires 2028-08-01 | Direct | 1,117 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 1,117 F5: On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.45 · Expires 2029-05-01 | Direct | 22,222 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 22,222 F6: On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.05 · Expires 2029-09-01 | Direct | 46,355 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 46,355 F7: On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.65 · Expires 2030-05-11 | Direct | 36,508 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 36,508 F8: On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,559 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 2,559 F9: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F10: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 8,443 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · Balance 8,443 F14: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F10: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 59,382 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · Balance 59,382 F10: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 42,159 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · Balance 42,159 F17: On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F10: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 89,013 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · Balance 89,013 F20: On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F10: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 19,508 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 19,508 F11: On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company. F10: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 25,330 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · Balance 25,330 F13: On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F10: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-02-23 | Direct | 42,344 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 42,344 F12: On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2035-02-21 | Direct | 107,450 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · Balance 107,450 F15: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F16: On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2036-03-01 | Direct | 147,804 |
Reported balance
Holding disclosure · report date 2026-09-01 · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · Balance 147,804 F18: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%. F19: On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the September 1, 2026 vesting of restricted stock.
F2: On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F3: On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F4: On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F5: On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F6: On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F7: On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date.
F8: On May 11, 2023, Ms. Olivo was granted 36,508 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F9: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F10: Once vested, the shares of common stock are not subject to expiration.
F11: On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at theapplicable measurement dates, subject to continued service with the Company.
F12: On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F13: On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period atthe applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of thecumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
F14: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F15: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%.
F16: On February 21, 2025, Ms. Olivo was granted 107,450 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F17: On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
F18: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%.
F19: On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date.
F20: On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 3, 2026 21:01 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,692 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-060499 · wk-form4_1788469286.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,875 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the September 1, 2026 vesting of restricted stock. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 3,944 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-034620 · wk-form4_1778703556.xml · derivative · entry 3 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,559 Underlying: Common Stock · 3,944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,559 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-034620 · wk-form4_1778703556.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,567 Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:19 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 3,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-034620 · wk-form4_1778703556.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2026 Filed May 5, 2026 20:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,042 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-030621 · wk-form4_1778012834.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,182 Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 89,013 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-014149 · wk-form4_1772579782.xml · derivative · entry 3 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,013 Underlying: Common Stock · 89,013 shares Expires not disclosed F3 · derivative.exercise_date: On March 1, 2026, Ms. Olivo was granted 89,013 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| March 01, 2026 Filed Mar 3, 2026 23:16 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 147,804 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001628280-26-014149 · wk-form4_1772579782.xml · derivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,804 Underlying: Common Stock · 147,804 shares Expires 2036-03-01 F1 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 27, 2026 and multiplied by 110%. F2 · derivative.exercise_date: On March 1, 2026, Ms. Olivo was granted 147,804 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 8,443 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011097 · wk-form4_1771967680.xml · derivative · entry 6 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,443 Underlying: Common Stock · 8,443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 3,323 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011097 · wk-form4_1771967680.xml · nonDerivative · entry 4 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,224 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011097 · wk-form4_1771967680.xml · nonDerivative · entry 3 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 21,079 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011097 · wk-form4_1771967680.xml · derivative · entry 5 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,159 Underlying: Common Stock · 21,079 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 8,295 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011097 · wk-form4_1771967680.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,104 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 21, 2026 Filed Feb 24, 2026 21:14 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 21,079 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011097 · wk-form4_1771967680.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,399 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 15,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002198 · wk-form4_1768512125.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,320 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 21:22 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 59,382 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-002198 · wk-form4_1768512125.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,465 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,977 | $0.00 Strike: $10.05 | $0.00 |
DisclosureSEC source: 0001628280-25-054270 · wk-form4_1764364698.xml · derivative · entry 3 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,355 Underlying: Common Stock · 8,977 shares Expires 2029-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 20,916 | $12.00 | $250,992.00 |
DisclosureSEC source: 0001628280-25-054270 · wk-form4_1764364698.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,083 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 25, 2025 Filed Nov 28, 2025 21:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,977 | $10.05 | $90,218.85 |
DisclosureSEC source: 0001628280-25-054270 · wk-form4_1764364698.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 20:18 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 4,918 | $10.00 | $49,180.00 |
DisclosureSEC source: 0001628280-25-045529 · wk-form4_1760991516.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,022 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 01, 2025 Filed Sep 3, 2025 20:12 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000165 · wk-form4_1756930372.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,940 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the September 1, 2025 vesting of restricted stock. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 20:38 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 14 | $0.00 | $0.00 |
DisclosureSEC source: 0001951869-25-000002 · wk-form4_1754426336.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,606 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the August 1, 2025 vesting of restricted stock. Read SEC document |
| May 11, 2025 Filed May 13, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 6,503 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000106 · wk-form4_1747166792.xml · derivative · entry 3 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,503 Underlying: Common Stock · 6,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2025 Filed May 13, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,584 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000106 · wk-form4_1747166792.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,620 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 11, 2025 Filed May 13, 2025 20:06 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 6,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000106 · wk-form4_1747166792.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| May 01, 2025 Filed May 5, 2025 20:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 652 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000081 · wk-form4_1746475516.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,701 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the May 1, 2025 vesting of restricted stock. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 8,443 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000043 · wk-form4_1740519666.xml · derivative · entry 5 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,886 Underlying: Common Stock · 8,443 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 2,504 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000043 · wk-form4_1740519666.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,353 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 21:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 8,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000043 · wk-form4_1740519666.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,857 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 63,238 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000043 · wk-form4_1740519666.xml · derivative · entry 4 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,238 Underlying: Common Stock · 63,238 shares Expires not disclosed F5 · derivative.exercise_date: On February 21, 2025, Ms. Olivo was granted 63,238 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:41 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 107,450 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001077183-25-000043 · wk-form4_1740519666.xml · derivative · entry 3 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,450 Underlying: Common Stock · 107,450 shares Expires 2035-02-21 F3 · derivative.exercise_price: This stock option was granted as a premium-price stock option. To calculate the premium exercise price we used the closing price on February 20, 2025 and multiplied by 110%. F4 · derivative.exercise_date: On February 21, 2025, Ms. Olivo was granted 107,450 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 21:11 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 59,382 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-25-000016 · wk-form4_1737061860.xml · derivative · entry 2 Olivo Alicia C · CIK 0001951869 · EVP, GC & Business Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,382 Underlying: Common Stock · 59,382 shares Expires not disclosed F2 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:43 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 5,175 | $15.36 | $79,475.06 |
DisclosureSEC source: 0001077183-24-000162 · wk-form4_1732056189.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,129 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: This balance includes 157 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| September 01, 2024 Filed Sep 4, 2024 20:08 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000146 · wk-form4_1725480484.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,147 F1 · shares: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy the tax obligations in connection with the September 1, 2024 vesting of restricted stock. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 20:17 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 1,040 | $16.05 | $16,695.43 |
DisclosureSEC source: 0001077183-24-000141 · wk-form4_1724098641.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,813 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: This balance includes 125 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 14 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000112 · wk-form4_1722888430.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,853 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the August 1, 2024 vesting of restricted stock. F2 · balance_after: This balance includes 378 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| May 15, 2024 Filed May 17, 2024 20:07 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 1,049 | $15.74 | $16,511.26 |
DisclosureSEC source: 0001077183-24-000079 · wk-form4_1715976399.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,867 Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 6,502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000074 · wk-form4_1715737126.xml · derivative · entry 4 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,006 Underlying: Common Stock · 6,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F4 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 6,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000074 · wk-form4_1715737126.xml · nonDerivative · entry 3 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,916 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,584 | $14.86 | $23,538.24 |
DisclosureSEC source: 0001077183-24-000074 · wk-form4_1715737126.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,414 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. Read SEC document |
| May 11, 2024 Filed May 15, 2024 01:39 UTC | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 6,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000074 · wk-form4_1715737126.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| May 11, 2024 Filed Dec 4, 2024 21:10 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionRestricted Stock Unit · Derivative | 6,502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000170 · wk-form4a_1733346644.xml · derivative · entry 3 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,006 Underlying: Common Stock · 6,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F5 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2024 Filed Dec 4, 2024 21:10 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 1,584 | $14.86 | $23,538.24 |
DisclosureSEC source: 0001077183-24-000170 · wk-form4a_1733346644.xml · nonDerivative · entry 2 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,414 F2 · shares: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units. F3 · balance_after: On May 14, 2024, the reporting person filed a Form 4 which inadvertently reported the number of shares received upon the vesting of certain of her RSUs twice. In fact, as reported in this amendment, the reporting person directly owned 39,414 shares of common stock after the vesting of 6,502 RSUs and reported withholding. The error effected the number of shares reported in Column 5 of Table I of each of the reporting person's subsequent filings on Form 4. Read SEC document |
| May 11, 2024 Filed Dec 4, 2024 21:10 UTC Amendment | NEOGENOMICS INC NEO · Entity 2096 | Exercise / conversionCommon Stock | 6,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000170 · wk-form4a_1733346644.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit is the economic equivalent of one share of NeoGenomics common stock and is converted into common stock upon vesting. Read SEC document |
| May 01, 2024 Filed May 3, 2024 20:10 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 652 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000061 · wk-form4_1714766994.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,496 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the May 1, 2024 vesting of restricted stock. F2 · balance_after: This balance includes 282 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 25,330 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000030 · wk-form4_1709069329.xml · derivative · entry 13 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,330 Underlying: Common Stock · 25,330 shares Expires not disclosed F13 · derivative.exercise_date: On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F9 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 25,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000030 · wk-form4_1709069329.xml · derivative · entry 12 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,329 Underlying: Common Stock · 25,329 shares Expires not disclosed F12 · derivative.exercise_date: On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F9 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:29 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 42,344 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001077183-24-000030 · wk-form4_1709069329.xml · derivative · entry 11 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,344 Underlying: Common Stock · 42,344 shares Expires 2034-02-23 F11 · derivative.exercise_date: On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:32 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 2,587 | $14.96 | $38,712.90 |
DisclosureSEC source: 0001077183-24-000013 · wk-form4_1708464760.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,866 F1 · balance_after: This balance includes 313 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 21:33 UTC | NEOGENOMICS INC NEO · Entity 2096 | SaleCommon Stock | 2,669 | $18.39 | $49,082.91 |
DisclosureSEC source: 0001077183-23-000140 · wk-form4_1700516026.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,140 F1 · balance_after: This balance includes 311 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| September 30, 2023 Filed Oct 3, 2023 21:50 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 14 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000127 · wk-form4_1696369845.xml · nonDerivative · entry 1 Olivo Alicia C · CIK 0001951869 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,498 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the September 30, 2023 vesting of restricted stock. F2 · balance_after: This balance includes 101 shares that were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.